Atyr Pharma Inc’s recently made public that its Director SCHIMMEL PAUL acquired Company’s shares for reported $0.61 million on Oct 08 ’25. In the deal valued at $0.90 per share,682,001 shares were bought. As a result of this transaction, SCHIMMEL PAUL now holds 1,095,024 shares worth roughly $1.06 million.
Then, SCHIMMEL PAUL bought 317,999 shares, generating $299,364 in total proceeds. Upon buying the shares at $0.94, the Director now owns 1,413,023 shares.
Before that, Gross Jane A bought 3,750 shares. Atyr Pharma Inc shares valued at $15,000 were divested by the Director at a price of $4.00 per share. As a result of the transaction, Gross Jane A now holds 9,750 shares, worth roughly $9457.5.
RBC Capital Mkts downgraded its Atyr Pharma Inc [ATYR] rating to a Sector perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who decreased its forecast for the stock in mid September from “an Overweight” to “an Equal weight”. Leerink Partners also remained covering ATYR and has decreased its forecast on September 15, 2025 with a “Market perform” recommendation from previously “an Outperform” rating. H.C. Wainwright revised its rating on September 15, 2025. It rated ATYR as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ATYR
On Monday, Atyr Pharma Inc [NASDAQ:ATYR] saw its stock fall -8.89% to $0.97. Over the last five days, the stock has gained 17.12%. Atyr Pharma Inc shares have fallen nearly -54.23% since the year began. Nevertheless, the stocks have fallen -73.32% over the past one year.
How much short interest is there in Atyr Pharma Inc?
A steep rise in short interest was recorded in Atyr Pharma Inc stocks on 2025-09-30, growing by 8.53 million shares to a total of 37.93 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 29.41 million shares. There was a rise of 22.48%, which implies that there is a positive sentiment for the stock.
